ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 503,27
-2,66%
Dow Jones
38 589,16
-0,15%
DAX
18 002,02
-1,43%
Brent Oil
82,275
0,00%
Bitcoin
66 010,86
0,01%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Mesoblast Limited (MESO)

  7. Mesoblast Limited (MESO) Actualités

MESO

Mesoblast (MESO)

Mesoblast Limited
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:MESO
DateHeureSourceTitreSymboleSociété
03/06/202402h23GlobeNewswire Inc.Mesoblast Corporate Presentation at Investor ConferenceNASDAQ:MESOMesoblast Limited
30/04/202403h05GlobeNewswire Inc.Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2024NASDAQ:MESOMesoblast Limited
26/03/202414h25AllPennyStocks.comFDA Commentary Sends Biotech Soaring During Premarket HoursNASDAQ:MESOMesoblast Limited
26/03/202403h34GlobeNewswire Inc.United States Food & Drug Administration (FDA) Notifies Mesoblast that Available Clinical Data from Phase 3 Trial Appear Sufficient to Support BLA Submission for Remestemcel-L in Children with Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)NASDAQ:MESOMesoblast Limited
14/03/202400h30GlobeNewswire Inc.Mesoblast Successfully Completes Placement and Accelerated Entitlement OfferNASDAQ:MESOMesoblast Limited
11/03/202400h54GlobeNewswire Inc.United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)NASDAQ:MESOMesoblast Limited
28/02/202423h57GlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023NASDAQ:MESOMesoblast Limited
26/02/202413h00GlobeNewswire Inc.Mesoblast Financial Results and Corporate Update WebcastNASDAQ:MESOMesoblast Limited
15/02/202401h46GlobeNewswire Inc.United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
01/02/202403h34Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:MESOMesoblast Limited
31/01/202403h13GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023NASDAQ:MESOMesoblast Limited
19/01/202401h28Dow Jones NewsMesoblast Gets FDA's Special Pediatric Designation for Revascor Heart TreatmentNASDAQ:MESOMesoblast Limited
19/01/202400h36GlobeNewswire Inc.United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
05/01/202403h57Edgar (US Regulatory)Form F-6 POS - Post-effective amendments for immediately effective filingNASDAQ:MESOMesoblast Limited
27/11/202300h56GlobeNewswire Inc.Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart DiseaseNASDAQ:MESOMesoblast Limited
22/11/202319h35AllPennyStocks.comBiotech Shares Soar Following Major AnnouncementNASDAQ:MESOMesoblast Limited
22/11/202300h32GlobeNewswire Inc.Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHDNASDAQ:MESOMesoblast Limited
31/10/202301h04GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023NASDAQ:MESOMesoblast Limited
26/09/202312h18GlobeNewswire Inc.Jane Bell AM Appointed Chair of Mesoblast Audit and Risk CommitteeNASDAQ:MESOMesoblast Limited
21/09/202309h30GlobeNewswire Inc.Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL ApprovalNASDAQ:MESOMesoblast Limited
06/09/202312h42Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:MESOMesoblast Limited
31/08/202301h07GlobeNewswire Inc.Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023NASDAQ:MESOMesoblast Limited
04/08/202315h03Dow Jones NewsMesoblast ADSs Plunge Premarket on Latest FDA RejectionNASDAQ:MESOMesoblast Limited
04/08/202302h10GlobeNewswire Inc.Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in ChildrenNASDAQ:MESOMesoblast Limited
31/07/202302h31GlobeNewswire Inc.Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023NASDAQ:MESOMesoblast Limited
06/06/202314h46Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:MESOMesoblast Limited
05/06/202302h21GlobeNewswire Inc.Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory RoleNASDAQ:MESOMesoblast Limited
30/05/202312h06Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:MESOMesoblast Limited
26/05/202301h28GlobeNewswire Inc.Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023NASDAQ:MESOMesoblast Limited
28/04/202303h00GlobeNewswire Inc.Appendix 4C Quarterly Activity ReportNASDAQ:MESOMesoblast Limited
 Showing the most relevant articles for your search:NASDAQ:MESO

Dernières Valeurs Consultées

EU
AI
Air Liquide
NYSE
DIS
Walt Disney
SPI
SP500
S&P 500
EU
PX1
CAC 40
COIN
ETHUSD
Ethereum
NASDAQ
AAPL
Apple
COIN
BTCUSD
Bitcoin
EU
BNP
BNP Paribas
EU
DG
Vinci
EU
BEL20
Bel 20
FTSE
UKX
FTSE 100
NASDAQ
NVDA
NVIDIA
EU
EN
Bouygues
EU
VIV
Vivendi
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés